ICAR Technologies:

High-Value Nutraceutical and

Nutritional Products from Seaweeds by Gopalakrishnan, A et al.
Indian Council of  
Agricultural Research
Seaweeds
ICAR Technologies:  
High-Value Nutraceutical and 
Nutritional Products from

Indian Council of  
Agricultural Research
Seaweeds
ICAR Technologies:  
High-Value Nutraceutical and 
Nutritional Products from
Editors:
A. Gopalakrishnan, C. N. Ravishankar, P. Pravin, J. K. Jena
October 2020
Editors
A. Gopalakrishnan
C. N. Ravishankar
P. Pravin
J. K. Jena
©Indian Council of Agricultural Research, New Delhi-110 001, India
Citation: Gopalakrishnan, A., C. N. Ravishankar, P. Pravin and J. K. Jena, 2020.  
ICAR Technologies: High-Value Nutraceutical and Nutritional Products from Seaweeds. 
Indian Council of Agricultural Research, New Delhi, India.      p.
Published by the Director, ICAR-Central Marine Fisheries Research Institute (CMFRI), Kochi-682 018 
on behalf of the Indian Council of Agricultural Research (ICAR), New Delhi-110 001, India
ICAR Technologies:  
High-Value Nutraceutical and Nutritional Products 
from Seaweeds
22
Seaweeds are valuable marine macro-flora having a wide range of commercial applications. Global production of seaweeds through mariculture in 2018 
was estimated at 32.4 million tonnes (wet weight) with a value of US$13.3 
billion. India’s marine ecosystem is bestowed with more than 0.26 million 
tonnes of wet harvestable biomass of seaweeds belonging to 700 species. 
Of these, nearly 60 species are economically important for their bioactive 
properties. India’s annual production of seaweed is approximately 22,000 
tonnes (wet weight) from aquaculture and wild sources. To further build on the 
progress made in this area, the country envisages diverse activities for enhancing 
seaweed production, augmenting livelihood activities of those dependent on 
the enterprise and developing optimal utilization strategies in the coming years. 
Recent research has provided evidence for the immense pharmaceutical 
potential of seaweeds due to their functionally diverse bioactive compounds. 
Realizing this vast potential, the Indian Council of Agricultural Research (ICAR) 
designed a comprehensive research strategy for economically viable seaweed-
based bioprospecting during the early 2000s. This strategy was operationalized 
through systematic research efforts undertaken by two Kochi-based research 
institutes of ICAR namely, ICAR-Central Marine Fisheries Research Institute 
(CMFRI) and ICAR-Central Institute of Fisheries Technology (CIFT). Earlier to that, 
ICAR-CMFRI pioneered the scientific cultivation of seaweeds at its Regional 
Centre located at Mandapam, Tamil Nadu. It gives me immense pleasure that 
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the recent research efforts of ICAR-CMFRI and ICAR-CIFT have yielded several 
health and nutraceutical products, many of which are commercialized through 
leading biopharma-companies. 
This compilation entitled “ICAR Technologies: High-Value Nutraceutical 
and Nutritional Products from Seaweeds” provides a lucid account of the 
technological profile of the nutraceutical products borne out of bioprospecting 
research carried out by ICAR-CMFRI and ICAR-CIFT. I compliment the 
contributors and congratulate the directors of the two ICAR institutes for their 
efforts in bringing out this important publication. Dr. J. K. Jena, DDG (Fisheries 
Science) has successfully coordinated the research on seaweeds and he deserves 
sincere appreciation. This valuable and timely publication is expected to serve 
the purpose of adequately informing all the stakeholders about the potential 
of seaweeds. This would spur further development in the rapid commercial 
utilization of seaweeds for human health, simultaneously contributing to 
enhanced income realization by the farmers.
(Trilochan Mohapatra)
 Secretary, DARE & Director General, ICAR
New Delhi
23-10-2020
he rich diversity of seaweeds in the Indian marine biosphere represents an 
untapped reservoir of bioactive compounds with valuable pharmaceutical and 
biomedical use. Over the last few years, the use of seaweeds for the development 
of new products and as a source for obtaining high-value compounds has attracted 
much interest from both food and pharmaceutical industries. The research team 
at ICAR-Central Marine Fisheries Research Institute (CMFRI), Kochi developed a 
hitherto unraveled database of seaweeds with small molecular weight bioactive 
molecules to combat various life-threatening diseases. This subsequently paved the 
way for the development of several nutraceutical products for use against arthritis, 
type-2 diabetes, dyslipidemia, hypothyroidism, osteoporosis, low immunity, and 
hypertension. The latest efforts in this line of research have yielded a seaweed-
based probiotic nutraceutical and an anti-bacterial ointment. ICAR-Central Institute 
of Fisheries Technology (CIFT), Kochi with its expertise in post-harvest processing 
and value addition has developed several seaweed-based products with anti-
inflammatory, anti-diabetic, anti-cancer and immune-modulating properties. 
Their product range also includes several seaweed-based ready-to-eat products, 
which are gaining popularity. Lately, the COVID-19 pandemic has prompted the 
researchers to develop a sanitizer with seaweed as a constituent.
Development of value-added products from underutilized seaweed species also 
has the potential to expand the opportunities for their downstream value chain 
augmentation, thereby boosting the livelihoods of resource-poor fisherfolk and 
budding entrepreneurs across the coastal belt. Coupled with a renewed policy 
Preface
T
focus of the Central Government, the seaweed-based value chain that is gaining 
momentum during recent times is poised to create new market opportunities in 
the country.
We are thankful to Dr. Trilochan Mohapatra, Secretary, DARE and Director 
General, ICAR for suggesting such a document and also for the consistent 
encouragement in bringing out this publication. We also wholeheartedly 
appreciate the efforts made by the research teams at ICAR-CMFRI and ICAR-
CIFT to develop an array of nutraceutical products and commercialize them. 
This compilation entitled “ICAR Technologies: High-Value Nutraceutical and 
Nutritional Products from Seaweeds” is a testimony to the accomplishments 
made so far in this realm by the two institutes. We wish the research teams all 
success and urge them to keep up the good work in times to come.
A. Gopalakrishnan
C. N. Ravishankar
P. Pravin
J. K. Jena
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Seaweeds constitute a large assemblage of species that predominate the coastal shelf areas of the southern Indian subcontinent and are often termed as the 
wonder herbs of the ocean due to their potential pharmaceutical properties. They 
are marine macrophytic thallophytes consisting of taxonomically distinguished 
groups of green (Chlorophyta), brown (Phaeophyta) and red (Rhodophyta) 
seaweeds. The commercially exploited seaweed species in India mainly include 
Gracilaria edulis, Gelidiella acerosa, Kappaphycus alvarezii, Sargassum spp. and 
Turbinaria spp. Seaweed farmers in India are generally small-scale farmers, and the 
main culture methods include either vegetative propagation using fragments from 
mother plants or by different kinds of spores. These marine macroflora are gaining 
immense attention in nutraceutical industries due to their protective function 
against various chronic diseases. Indian nutraceuticals market has been growing at 
the compound annual growth rate of 20 percent for the past three years, particularly 
in the segments of functional food products, antioxidants, and immunity boosters. 
These developments point towards the fast proliferation of the specific segments of 
nutraceuticals in India and its acceptance by the Indian consumers and healthcare 
providers. With increasing health awareness and the shift towards preventive health 
care, India’s future in this segment is promising. Recent efforts by the government 
to bring about clarity in regulatory protocols with regard to nutraceutical products 
have also augmented the rapid growth of this segment. 
The most interesting marine phyla with respect to pharmacologically active marine 
compounds include the abundantly available seaweed species, which are potential 
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Aerial view of seaweed farm, Thondi, Tamil Nadu
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sources of bioactive substances. Novel secondary bioactive metabolites from the 
seaweeds address the concerns about the toxic effects of synthetic drugs to a great 
extent. Considering this, ICAR-Central Marine Fisheries Research Institute (CMFRI) 
and ICAR-Central Institute of Fisheries Technology (CIFT) designed specialized 
research programmes to systematically probe these candidate seaweed species for 
their relevance to human health. The continued research efforts at these institutes 
helped in the identification of a library of bioactive molecules from seaweeds for use 
against various life-threatening diseases. Further applications of these compounds 
lead to the development of an array of nutraceutical, nutritional and anti-bacterial 
formulations. 
This booklet is an attempt to present the specific technological profile of the 
seaweed-based products borne out of the research efforts carried out by ICAR-
CMFRI and ICAR-CIFT.
Harvested seaweed rope
Representative images of brown seaweed Sargassum wightii collected from the Palk Bay region of Mandapam, Tamil Nadu
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Cadalmin® GAe 
About the product
 l Cadalmin® GAe is an anti-arthritic nutra-
ceutical; combats joint pain and arthritis.
 l Contains 100% natural marine bioactive 
ingredients extracted from selected 
brown seaweeds, viz., Turbinaria ornata 
and Turbinaria conoides.
 l The bioactive ingredients in Cadalmin® GAe 
competitively inhibit pro-inflammatory 
cyclooxygenase-2 and lipoxygenase.
 l Decreases production of inflammatory 
prostaglandins and leukotrienes, thereby 
hindering the occurrence of inflamma-
tory pain and arthritis.
 l The efficacy of the product was tested 
and compared with that of standard 
drugs (non-steroidal anti-inflammatory 
drugs) through animal test models.
 l It has no side effects as proved from the 
preclinical and acute/long-term chronic 
toxicity studies.
 l Unique biochemical engineering 
techniques are adopted which assure 
higher shelf-life.
 l The active ingredients are purified and 
concentrated and packed in plant-based 
capsules to meet the dietary needs 
of vegetarians. Each capsule contains 
350 mg of active ingredients.
Commercialization and availability
 l It is a patented technology of ICAR-
CMFRI, Kochi; commercialized in 2020 
to the Pioneer Pharmaceuticals Limited 
(a Pharmaceutical Company) in Kochi, 
Kerala, India.
 l The product is marketed as Green Algal 
Extract (GAe)
1. Cadalmin® GAe – Antiarthritic Nutraceutical
Compiled by: Kajal Chakraborty, P. Vijayagopal and Shinoj Parappurathu 
Further Information: Director, ICAR-Central Marine Fisheries Research Institute, Kochi, Kerala. Phone: +91-484-2394798 
Email: director.cmfri@icar.gov.in; Website: www.cmfri.org.in
Turbinaria ornata Turbinaria conoides
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Cadalmin®ADe
About the product
 l Cadalmin® ADe is an anti-diabetic nutra-
ceutical; combats type-2 diabetes.
 l Contains 100% natural marine bioactive 
ingredients extracted from selected 
brown seaweeds, viz., Sargassum wightii 
and Turbinaria ornata.
 l The bioactive ingredients in Cadalmin® ADe 
competitively inhibit dipeptidyl peptidase-IV 
and tyrosine phosphatase 1B.
 l Decreases production of various mediators 
responsible for inducing type-2 diabetes, 
and interferes with the release of simple 
sugars from the gut. This further reduces 
postprandial hyperglycemia, thereby 
hindering the occurrence of type-2 
diabetes.
 l The efficacy of the product was compared 
with that of a standard drug (glibencla-
mide) through animal test models.
 l Detailed preclinical and acute/long-term 
chronic toxicity studies revealed no side- 
effects.
 l Higher shelf-life of the product is ensured 
through unique biochemical engineering 
techniques.
 l The purified and concentrated active 
ingredients (350 mg) are packed in plant-
based capsules (cellulose-based hyper-
melose) to satisfy the dietary require-
ments of vegetarians.
Commercialization and availability
 l It is a patented technology of ICAR-
CMFRI, Kochi; commercialized in 2020 
to the Pioneer Pharmaceuticals Limited 
(a Pharmaceutical Company) in Kochi, 
Kerala, India.
 l The product is marketed as Antidiabetic 
Extract (ADe)
2. Cadalmin® ADe – Antidiabetic Nutraceutical
Compiled by: Kajal Chakraborty, P. Vijayagopal and Shinoj Parappurathu 
Further Information: Director, ICAR-Central Marine Fisheries Research Institute, Kochi, Kerala. Phone: +91-484-2394798 
Email: director.cmfri@icar.gov.in; Website: www.cmfri.org.in
Turbinaria ornata Sargassum wightii
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Cadalmin® ACe
About the product
 l Cadalmin® ACe is an anti-dyslipidemic 
nutraceutical; combats dyslipidemia.
 l Contains 100% natural marine bioactive 
ingredients extracted from selected 
brown seaweed, viz., Sargassum wightii.
 l The bioactive ingredients in Cadalmin® 
ACe competitively inhibit hydroxymethyl 
glutaryl coenzyme A reductase, various 
target receptors and other limiting 
enzymes, thereby hindering the occur-
rence of dyslipidemia.
 l Attenuates high fat-induced hyper-
lipidemia, characterized by a signifi-
cantly lower level of serum LDL, lipid 
peroxidation status and lower athero-
genic index.
 l The efficacy of the product was compared 
with that of a standard drug (Atorvas-
tatin®) through animal test models.
 l No side effects were recorded from the 
preclinical and acute/long-term chronic 
toxicity experiments.
 l Unique biochemical engineering methods 
are employed to ensure higher shelf-life.
 l A total of 350 mg purified and concen-
trated active ingredients in the product 
are packed in plant-based capsules to 
meet the dietary needs of vegetarians.
Commercialization and availability
 l It is a patented technology of ICAR-
CMFRI, Kochi; commercialized in 2017 
to the VLCC (Vandana Luthra Curls and 
Curves) Well Science Limited (a leading 
Indian MNC in wellness and obesity 
management) at Gurgaon, India.
 l The product is marketed as Antihyper-
cholesterolemic Extract (ACe).
3. Cadalmin® ACe – Antihypercholesterolemic Nutraceutical
Compiled by: Kajal Chakraborty, P. Vijayagopal and Shinoj Parappurathu 
Further Information: Director, ICAR-Central Marine Fisheries Research Institute, Kochi, Kerala. Phone: +91-484-2394798 
Email: director.cmfri@icar.gov.in; Website: www.cmfri.org.in
Sargassum wightii
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Cadalmin® ATe
About the product
 l Cadalmin® ATe is an anti-hypothyroid 
nutraceutical; combats hypothyroid 
disorder.
 l The product is developed from 100% 
natural marine bioactive ingredients 
isolated from selected brown seaweeds, 
viz., Sargassum wightii, Turbinaria ornata, 
Turbinaria conoides, and red seaweed 
Kappaphycus alvarezii.
 l The bioactive ingredients in Cadalmin® 
ATe stimulate thyroid releasing hormone 
and increase the activity of selenodeiodi-
nase to produce metabolically active 
triiodothyronine, thereby hindering the 
occurrence of the hypothyroid disorder.
 l The efficacy of the product was compared 
with that of a standard drug (Levothy-
roxin®) through animal test models.
 l It has no side effects as proved from the 
preclinical and acute/long-term chronic 
toxicity studies.
 l Unique biochemical engineering 
techniques are adopted which assure 
higher shelf-life.
 l Plant-based capsules containing 350 mg 
of purified and concentrated active 
ingredients are packed to meet the 
dietary needs of vegetarians.
Commercialization and availability
 l This patented technology of ICAR-CMFRI, 
Kochi was commercialized in 2018 to the 
VLCC (Vandana Luthra Curls and Curves) 
Well Science Limited (a leading Indian 
MNC in wellness) at Gurgaon, India.
 l The product is marketed as Antihypothy-
roid Extract (ATe).
4. Cadalmin® ATe – Antihypothyroid Nutraceutical
Compiled by: Kajal Chakraborty, P. Vijayagopal and Shinoj Parappurathu 
Further Information: Director, ICAR-Central Marine Fisheries Research Institute, Kochi, Kerala. Phone: +91-484-2394798 
Email: director.cmfri@icar.gov.in; Website: www.cmfri.org.in
Sargassum wightii Turbinaria ornata Turbinaria conoides Kappaphycus alvarezii 
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Cadalmin® AHe
About the product
 l Cadalmin® AHe is an anti-hypertensive 
nutraceutical; combats pathophysiologies 
related to hypertension.
 l Selected brown seaweed, viz., Sargassum 
wightii was used to isolate 100% natural 
marine bioactive ingredients for developing 
the product.
 l The bioactive ingredients in Cadalmin® 
AHe competitively inhibit the angiotensin- 
converting enzyme that converts 
angiotensin I to angiotensin II. Decreased 
production of angiotensin II, lowers blood 
pressure and prevents remodeling of 
smooth muscle and cardiac myocytes.
 l Modulates production of serum level of 
oxidative stress marker nitric oxide and 
lipid peroxidase.
 l The efficacy of the product was compared 
with that of a standard drug (Telmisartan®) 
through animal test models.
 l Acute/long-term chronic toxicity and 
preclinical studies revealed no side effects 
for the product.
 l Unique biochemical engineering 
techniques are adopted to ensure higher 
shelf-life.
 l The active ingredients are purified and 
concentrated and packed in plant-based 
capsules to meet the dietary needs 
of vegetarians. Each capsule contains 
350 mg of active ingredients.
Commercialization and availability
 l The patented technology of ICAR-CMFRI, 
Kochi was licenced to the Pioneer Phar-
maceuticals Limited (a Pharmaceutical 
Company), Kochi, Kerala, during 2020.
 l The product is marketed as Antihyperten-
sive Extract (AHe).
5. Cadalmin® AHe – Antihypertensive Nutraceutical
Compiled by: Kajal Chakraborty, P. Vijayagopal and Shinoj Parappurathu 
Further Information: Director, ICAR-Central Marine Fisheries Research Institute, Kochi, Kerala. Phone: +91-484-2394798 
Email: director.cmfri@icar.gov.in; Website: www.cmfri.org.in
Sargassum wightii
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Cadalmin® AOe
About the product
 l Cadalmin® AOe is an anti-osteoporotic 
nutraceutical; combats osteoporosis.
 l Contains 100% natural marine bioactive 
ingredients extracted from selected red 
seaweed, viz., Gracilaria salicornia and 
brown seaweed, viz., Sargassum wightii.
 l The bioactive ingredients in Cadalmin® 
AOe increase the activity of alkaline 
phosphatase and bone morphogenic 
protein, along with higher serum oste-
ocalcin levels and prominent minerali-
zation, which were corroborated with 
increases in bone mineral density and 
found to be effective for bone health 
development.
 l Effectively suppresses the osteoclast 
activity (degradation of mineral on the 
bone surface), which is related to oste-
oblastic cell formation in bone tissue to 
combat osteoporotic related disorders 
and improve bone health.
 l The efficacy of the product was compared 
with that of a standard drug (Sodium 
Alendronate®) through animal test 
models.
 l It has no cytotoxicity across all the tested 
concentrations from 150 to 1000 μg/mL 
through animal test models.
 l Unique biochemical engineering 
techniques are adopted to ensure higher 
shelf-life.
 l Plant-based capsules are used to pack 
the purified and concentrated active 
ingredients (350 mg), thereby ensuring the 
dietary needs of vegetarians.
Commercialization and availability
 l It is a patented technology of ICAR-
CMFRI, Kochi; scheduled for licensing 
during 2020.
 l The product will be marketed as Antios-
teoporotic Extract (AOe).
6. Cadalmin®AOe – Antiosteoporotic Nutraceutical
Compiled by: Kajal Chakraborty, P. Vijayagopal and Shinoj Parappurathu 
Further Information: Director, ICAR-Central Marine Fisheries Research Institute, Kochi, Kerala. Phone: +91-484-2394798 
Email: director.cmfri@icar.gov.in; Website: www.cmfri.org.in
Gracilaria salicornia Sargassum wightii
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Cadalmin® IBe
About the product
 l Cadalmin® IBe is a novel immunity- 
boosting nutraceutical; helps to improve 
the non-specific innate immune system.
 l The product contains 100% natural 
marine bioactive ingredients extracted 
from selected brown seaweeds, viz., 
Turbinaria conoides and Sargassum 
wightii.
 l The bioactive ingredients in Cadalmin® IBe 
increase innate immune response in animal 
models by regulating nuclear factor kappa-B 
along with oxidative stress markers.
 l Cadalmin® IBe effectively suppresses the 
oxidative agents causing the production 
of reactive oxygen species that could result 
in the reduced inflammatory response and 
benefits the immune system.
 l The efficacy of the product was compared 
with that of a standard drug (Naproxen®) 
through animal test models.
 l No side effects were recorded in the 
preclinical and acute/long-term chronic 
toxicity experiments.
 l Unique biochemical engineering 
techniques are adopted resulting in 
higher shelf-life.
 l The active ingredients are purified and 
concentrated; a total of 350 mg of these 
ingredients are packed in plant-based 
capsules to meet the dietary needs of 
vegetarians.
Commercialization and availability
 l Patent application has been filed for the 
technology. It is scheduled for licensing 
during 2020.
 l The product will be marketed as Immuno- 
boost Extract (IBe). Can be promoted as 
a novel immunity booster, which is 100% 
natural.
7. Cadalmin® IBe – Immune Booster
Compiled by: Kajal Chakraborty, P. Vijayagopal and Shinoj Parappurathu 
Further Information: Director, ICAR-Central Marine Fisheries Research Institute, Kochi, Kerala. Phone: +91-484-2394798 
Email: director.cmfri@icar.gov.in; Website: www.cmfri.org.in
Sargassum wightiiTurbinaria conoides
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Cadalmin® ABe
About the product
 l Cadalmin® ABe is an antimicrobial skin 
and topical wound care ointment; it heals 
the wound and reduces the likelihood of 
secondary infections.
 l Contains 100% natural marine bioactive 
ingredients extracted from selected red 
seaweed, viz., Kappaphycus alvarezii and 
seaweed-associated Firmicutes.
 l The bioactive ingredients in Cadalmin® ABe 
inhibit methicillin-resistant Staphylococcus 
aureus, increases the proliferation of fibro-
blasts into the wound site and complete 
closure of the incised wound.
 l The efficacy of the product was compared 
with that of a standard drug (Clinda-
mycin®) through antibacterial cell-line 
test models.
 l Cadalmin® ABe is proved to be non-toxic 
on fibroblast cell lines, and there was 
no growth of pathogenic microbes by 
storage of the ointment at room temper-
ature.
 l It helps in cleansing wounds, promotes 
a moisture balanced environment and 
protects wounds from becoming dry. It 
also helps the natural healing leading to 
faster relief of pain and inflammation.
 l The purified and concentrated active 
ingredients are packed as ointment in a 
tube.
Commercialization and availability
 l Patent application has been filed for the 
technology. It is scheduled for licensing 
during 2020.
 l The product will be marketed as Antibac-
terial Extract (ABe).
8. Cadalmin® ABe – Antibacterial Skin Care Ointment
Compiled by: Kajal Chakraborty, P. Vijayagopal and Shinoj Parappurathu 
Further Information: Director, ICAR-Central Marine Fisheries Research Institute, Kochi, Kerala. Phone: +91-484-2394798 
Email: director.cmfri@icar.gov.in; Website: www.cmfri.org.in
Kappaphycus alvarezii 
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Cadalmin® MBc
About the product
 l Cadalmin® MBc is an antimicrobial 
therapeutic composition for oral 
consumption; a probiotic that inhibits 
intestinal pathogens.
 l The product is developed from 100% 
natural marine bioactive ingredients 
extracted from seaweed-associated 
Bacillus amyloliquefaciens MB6 along 
with extract of red seaweed, viz., 
Kappaphycus alvarezii.
 l The composition contains oligosaccharide, 
prebiotics, antioxidants/phenolic derivative 
enriched oleoresin and probiotic micro-
flora that are individually present in the 
therapeutic concentrate at a concentration 
of 1 x 106 to 1 x 1010 CFU.
 l Able to survive gastric pH up to 3 hours, 
and can be considered as a good 
probiotic for use in food preparations for 
preventing the harmful gut pathogenic 
infections.
 l Cadalmin® MBc is capable of inhibiting 
intestinal pathogens and is useful for 
re-establishing beneficial bacteria in the 
body’s intestinal tract.
 l The efficacy of the product was compared 
with that of a standard drug (ViBact®).
 l Unique biochemical engineering 
techniques are adopted to ensure higher 
shelf-life.
 l Plant-based capsules are used to pack 
the purified and concentrated active 
ingredients (300 mg/capsule) to meet the 
dietary needs of vegetarians.
Commercialization and availability
 l Patent application has been filed for the 
technology. It is scheduled for licensing 
during 2020.
 l The product will be marketed as Maribac 
(MBc).
9. Cadalmin® MBc – Probiotic Supplement
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CIFTEQ® FucoidanEx 
About the product
 l CIFTEQ® FucoidanEx is a freeze-dried 
supplement, rich in high-value nutraceu-
tical Fucoidan and micronutrients. It forms 
as an ingredient in various nutraceuticals 
and cosmetic products.
 l The product extracted from Sargassum 
wightii is also a source of essential 
micronutrients, taurine and antioxidant 
pigment fucoxanthin.
 l The product has been characterized using 
advanced chromatographic and mass 
spectrometric techniques in terms of its 
content of fucoidan, essential micro- 
elements such as zinc, iron, and calcium, 
water-soluble vitamins, amino acids, 
brown pigment fucoxanthin and taurine.
 l A process using green chemistry principles 
has been developed for the extraction of 
bioactive polysaccharide Fucoidan from 
brown seaweed with high yield.
 l A novel enzymatic extraction technique 
is used, followed by enrichment of 
Fucoidan using ion exchange resins. No 
harmful organic solvents are used for the 
production of the extract.
 l Fucoidan has been recognized as a novel 
food ingredient in EU and USA.
 l The preclinical study conducted in ICAR-
CIFT showed excellent in vivo antioxidant 
activity and showed no signs of adverse 
effect even at higher doses.
Commercialization and availability
 l The product has been licensed to M/s. 
Amalgam Foods Pvt. Ltd. The company 
has acquired the license to sell the 
product as a novel food ingredient in the 
European Union.
 l The company is marketing the product as 
an active ingredient in nutraceuticals and 
cosmeceuticals products
10. CIFTEQ® FucoidanEx – Dietary Supplement
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CIFTEQ® FucoTeaEx 
About the product
 l CIFTEQ® FucoTeaEx is a natural dietary 
supplement containing the goodness of 
Fucoidan from brown seaweed and green 
tea phenolics.
 l The supplement, which is a source of 
naturally available antioxidants, vitamins 
and minerals, is developed using a 
novel microencapsulation technology to 
enhance bioavailability.
 l The product is prepared using the 
principles of green chemistry, and the 
supplement is 100% organic solvent 
residue-free. Each capsule provides a 
minimum of 90 mg Fucoidan.
 l A novel enzymatic extraction technique is 
used which is followed by enrichment of 
Fucoidan using Ion exchange resins.
 l No harmful organic solvents are used for 
the production of the extract.
 l An equimolecular blend of fucoidan and 
green tea extract is formulated using a 
novel microencapsulation technique to 
improve stability and ease of delivery.
 l Several preclinical studies have shown 
that fucoidan has excellent anti- 
inflammatory, anti-diabetic, anti-cancer, 
and immune-modulating activities.
 l The preclinical study conducted in ICAR-
CIFT showed that the product attenuates 
the effect of drug-induced myocardial 
infarction.
Commercialization and availability
 l The product has been licensed to M/s. 
Bodinanaturals Pvt. Ltd., Kerala. The 
company has started production and will 
market the supplement under the trade 
name ‘Seavina’.
 l The company is promoting the product as 
a dietary supplement intended to manage 
cardiac health.
11. CIFTEQ® FucoTeaEx – Microencapsulated Dietary Supplement
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CIFTEQ® Seaweed Nutridrink
About the product
 l CIFTEQ® Seaweed Nutridrink is a 
reconstitutable formulation of seaweed 
(Sargassum wightii) and grape juice. The 
drink is rich in fucoidan, which has estab-
lished health benefits.
 l The technology resulted in the value- 
addition of fruit juices and high-value 
utilization of seaweeds.
 l The Nutridrink is also a source of bioactive 
carotenoid fucoxanthin and seaweed 
polyphenols.
 l A 20% blend of seaweed extract with 
grape juice was microencapsulated to 
result in a reconstitutable powder.
 l The powder instantaneously solubilizes in 
water to provide the ‘Seaweed Nutridrink’. 
The microencapsulation process adds to 
the stability and ease of packaging of the 
product.
 l The Nutridrink possesses a significantly 
higher amount of Riboflavin and 
Pantothenic acid, and also appreciable 
quantities of Taurine, a free amino acid 
with known nutraceutical properties.
 l The addition of seaweed extract in fruit 
juice also improves the content of nutri-
tionally-essential elements such as iron 
and calcium.
 l The technology is aimed at the inter- 
nationally rapidly growing health 
promoting beverages industry. Many 
different combination formulations have 
been developed with seasonal and mixed 
fruit juices.
Commercialization and availability
 l The product has been licensed to Kerala 
Nutraceuticals Pvt. Ltd., Kerala. The 
company will market the product as a 
health promoting beverage formulation.
12. CIFTEQ® Seaweed Nutridrink
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 CIFTEQ® Seaweed Cookies 
About the product
 l Caulerpa racemosa, commonly known 
as sea grapes, is a green seaweed that 
possesses various physiological benefits. 
 l The seaweed is one of the salubrious 
foods consumed traditionally by the 
coastal populations.
 l This seaweed is a good source of essential 
minerals like calcium, iron and magnesium, 
and natural antioxidants.
 l In traditional and folk medicine, Caulerpa 
has been widely known to treat high 
blood pressure and rheumatism.
 l Cookies with Caulerpa racemosa as an 
ingredient, offer a unique and innovative 
approach towards the utilization of 
seaweed as a functional food.
 l The cookies are rich in protein and dietary 
fibre contents, along with high phenolic 
content and antioxidative potential.
 l Seaweed cookies provide the option for 
market diversification of seaweed in the 
form of a healthy biscuit.
 l The technology is aimed at the global 
healthy biscuit market, which is valued at 
2.2 billion US$ and is expected to grow 
at an annual rate of 5% between 2019 
to 2025.
Commercialization and availability
 l The product has been commercialized to 
M/s ZCorp. Organic Pvt. Ltd., Palakkad, 
Kerala, and M/s Zaara Biotech, Thrissur, 
Kerala.
 l The company has started marketing the 
product as organic cookies for promoting 
digestive health
13. CIFTEQ® Seaweed Cookies
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 CIFTEQ® Seaweed Yoghurt
About the product
 l Sargassum wightii, a brown seaweed, is 
rich in fucoidan which is a fucose-rich 
sulphated polysaccharide possessing 
various physiological properties. It has 
got potential applications in the formu-
lation of functional and nutraceuticals 
products.
 l Fucoidan possesses several bioactivities 
i.e., anti-cancer, anti-thrombotic, anti-
virus, antioxidant, anti-inflammatory, 
anti-diabetic and neuroprotective 
functions.
 l Fucoidan is effectively extracted from 
Sargassum wightii using a novel ultra- 
sonication assisted extraction procedure 
and is supplemented in the yoghurt 
formulation. 
 l The extract is completely biocompatible 
as proven in in vitro and in vivo studies. 
No harmful organic solvent is used for 
extraction.
 l Fucoidan-enriched yoghurt exhibits 
good phenolic content and antioxidative 
potential.
 l The enrichment with fucoidan 
has minimal effect on the sensory 
characteristics of yoghurt.
 l The seaweed yoghurt has got high 
acceptance among consumers. Yoghurt 
acts as an efficient delivery system for 
seaweeds’ physiological benefits in the 
human diet.
 l The technology is aimed at the global 
fortified yogurt market, which is expected 
to garner a revenue of US$ 10 billion 
by 2024, with an annual growth rate of 
approximately 6.5%.
Commercialization and availability
 l The product is licensed to Kerala Co- 
operative Milk Marketing Federation 
(MILMA). The company is scheduled 
to market the product as a functional 
Yoghurt.
14. CIFTEQ® Seaweed Yoghurt
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CIFTEQ® Extruded snacks
About the product
 l Sargassum wightii is a brown seaweed 
with high levels of essential macro- and 
micro-nutrients, trace minerals, dietary 
fibres and antioxidants.
 l Powdered S. wightii is incorporated in 
dried form to rice/corn-based extruded 
snacks.
 l The extruded product has optimal physical 
and functional properties viz., lower bulk 
density, higher expansion ratio and hard-
ness, similar to other extruded products.
 l The product is rich in minerals, 
carbohydrate and dietary fibre, and 
has high total phenolic content and 
antioxidant capacity, which are beneficial 
for human health.
 l This seaweed enriched and extruded 
product can be coated with different 
flavours using sunflower oil for better 
consumer acceptability.
 l The product packed in metalized polyes-
ter-polyethylene pouches has a storage 
life of 6 months at ambient storage 
conditions.
 l The process parameters and packaging 
parameters are optimized to ensure 
microbiological safety and extend the 
shelf-life.
 l Extruded snacks products are highly 
popular among urban youth despite 
being high in calorie and low in nutrition. 
The technology is aimed at making such 
snacks healthier and nutritious.
Commercialization and availability
 l The technology is validated and ready for 
commercialization.
 l A mini process line starting from 
production to packaging is available for 
demonstration to interested entrepreneurs.
15. CIFTEQ® Seaweed Incorporated Extruded Snacks
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CIFTEQ® Seaweed Aqua Booster
About the product
 l CIFTEQ® Seaweed Aqua Booster is a spray-
dried powder that consists of seaweed 
crude extract, chitosan and vanillic 
acid. Chitosan-vanillic acid conjugate 
is added as a natural antioxidant and 
stabilizer.
 l It is recommended that the seaweed 
Aqua Booster is fortified at a 1% level in 
fish feed formulations.
 l The product is used as an aquaculture feed 
supplement. The bioactive compounds in 
the aqueous extracts of Sargassum spp. are 
known for their bio-functional properties 
such as antimicrobial, antiviral, anti- 
inflammatory and antioxidant capacity.
 l The seaweed crude extract is prepared 
from the brown seaweed Sargassum 
wightii by hot water extraction method 
followed by mixing with vanillic acid cross- 
linked chitosan solution. The solution is 
spray-dried to obtain in powder form.
 l The in vivo studies conducted in ICAR-
CIFT demonstrated that the product 
improves growth, immunity and health 
performance and helps to mitigate the 
thermal and physiological stress of fish 
and shellfish and also reduces the faecal 
disintegration.
 l The novel immune stimulant improves 
the health performance of aquaculture 
shrimp, thus improving yield.
Commercialization and availability
 l The technology has been validated in the 
field and ready for commercialization.
 l A pilot-scale process is ready 
for demonstration to interested 
entrepreneurs. The product can be 
marketed as a novel immune-stimulating 
aquaculture feed supplement.
16. CIFTEQ® Seaweed Aqua Booster – Fish Feed Supplement
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16. CIFTEQ® Seaweed Aqua Booster – Fish Feed Supplement
CIFTEQ® Seaweed Dietary Fibre
About the product
 l Dietary fibre is extracted from red seaweed 
Gracilaria edulis using a combination of 
enzymatic and chemical methods.
 l It is a promising bioactive ingredient with 
wide applications in the functional food 
industry.
 l Dietary fibres are widely known to 
reduce coronary artery ailments, diabetes 
incidence, gut neoplasia, prevention of 
constipation and the risk of colon cancer.
 l This product contains 96% total dietary 
fibre content and has good functional 
properties such as water holding capacity, 
swelling capacity and oil holding capacity.
 l Dietary fibre from G. edulis is colour-
less and odourless and hence, does not 
interfere with the sensory attributes of 
the products intended for fortification.
 l Several functional and ready to cook 
products such as sausages and noodles 
have been developed incorporating the 
seaweed dietary fibre.
 l A pilot-scale process line for demonstra-
tion of the functional products is available 
for interested entrepreneurs. Shelf-life 
and microbiological safety of the devel-
oped products have been established.
Commercialization and availability
 l The technology has been validated and the 
product is ready for commercialization.
 l The products will be marketed as 
functional food, promoting digestive 
health.
17. CIFTEQ® Seaweed Dietary Fibre
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CIFTEQ® Seaweed edible sachet
About the product
 l Seaweeds are rich in proteins, dietary fibre, 
polysaccharides, vitamins, minerals as 
well as important bioactive compounds. 
The edible and biodegradable sachet/film 
developed from seaweed is a novel food 
packaging solution.
 l Seaweeds such as Kappaphycus alvarezii 
and Ulva reticulata are essential bio- 
resources for phycocolloids extraction. 
 l A technology has been developed for 
the preparation of edible and functional 
sachet using these seaweeds.
 l The sachets are developed by film casting 
method. The film-forming solution is 
obtained by dissolving seaweed powder 
of U. reticulata and K. alvarezii, and 
sodium alginate along with sorbitol as 
the plasticizer. The homogenized solution 
is finally cast as a film.
 l Seaweed-based functional and edible 
films exhibit good sealing and antioxidant 
properties. Therefore the novel packaging 
material can be used as soluble sachets/
pouches/bags for seasonings in instant 
noodles, and for packing instant coffee/
tea, etc. in the food industry.
 l The seaweed-based packaging sachet 
adds up the nutritional and functional 
value of the food product by acting as 
an antioxidant and antimicrobial agent, 
thereby improving the quality and pres-
ervation of food.
 l The technology is intended to reduce 
the use of plastic in ready to eat food 
packaging, thereby reducing solid waste 
generation.
Commercialization and availability
 l The technology has been validated and the 
product is ready for commercialization.
18. CIFTEQ® Seaweed Edible Sachet
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Packaging material 
About the product
 l Majority of the modern-day packaging 
materials are composed of fossil-based 
polymers which are hazardous for the 
environment.
 l Biopolymers provide an excellent 
alternative material to petroleum-derived 
polymers, being ecofriendly, non-toxic and 
renewable. 
 l Though biopolymer-based films can be 
prepared from proteins, carbohydrates and 
lipids, carbohydrate-based films are the 
most preferred because of their colloidal 
properties and better film-forming ability.
 l Seaweed extract based packaging 
materials are prepared from the poly-
saccharide of the red seaweed Gracilaria 
edulis and Gelidiella acerosa and brown 
seaweed Sargassum wightii.
 l The seaweed-based bioplastics exhibit 
good physical, thermal and barrier 
properties and are ideal for packing a 
variety of food products.
 l These bioplastics are biodegradable, 
eco-friendly, naturally available, renewable 
and cheaper. The products serve as 
an alternative to the petroleum-based 
plastics.
 l The packaging materials can be prepared 
in various combinations with fish protein/ 
antioxidants / natural antimicrobial agent/ 
flavouring additives to make them edible 
and bio-functional.
Commercialization and availability
 l The technology has been validated and 
ready for commercialization.
 l A process workflow is ready for demo- 
nstration to interested entrepreneurs. 
19. CIFTEQ® Seaweed-based Packaging Materials
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CIFTEQ® Seaweed Hand Sanitizer
About the product
 l Carrageenan, an important prospective 
marine polysaccharide, extracted from 
marine red algae, is having a wide 
range of applications in the field of 
food, cosmetics, pharmaceutical and 
biomedical industries.
 l The formulations of seaweed-based 
products have also been found to be 
active against several enveloped viruses 
like herpes virus, cytomegalovirus, 
influenza virus and HIV.
 l The seaweed-based hand sanitizer is 
developed as a preventive hygienic 
measure to attenuate the incidence of 
the corona virus infection affecting the 
people massively all over the world.
 l The hand sanitizer contains a novel 
amphiphilic succinyl chitosan derivative 
as moisturizer and excipient.
 l The sanitizer comprises isopropyl alcohol 
(above 75%) and 0.2% carrageenan 
(extracted from red seaweed Kappaph-
ycus alvarezii) found to have pronounced 
antimicrobial and antiviral properties.
 l In addition to improving the hygiene 
standards of people, the product ensures 
the effective utilization of seaweeds.
Commercialization and availability
 l The technology of seaweed-based hand 
sanitizers is licensed to M/s. Kerala 
Nutraceutical Pvt Ltd. and the product is 
available in the market.
 l The product is being marketed as a skin- 
friendly hand sanitizer under the trade 
name “Zafora”. 
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